Dr Reddy's LaboratoriesDRREDDY

DRREDDYDr Reddy's Laboratories₹1,269▼ 0.55% today

Nifty 50

Dr Reddy's Laboratories is a major pharma company strong in US generics and APIs.

Key products	Generics, APIs, biosimilars, OTC and consumer health.
Geography	US, India, Russia/CIS and emerging markets.
Competitors	Sun Pharma, Cipla, Lupin.

AI-generated overview — verify before relying on it.

Net institutional flow

+₹0 Cr

Institutional buyers

1 in / 1 out

High-impact filings

0 · tilt Neutral

Next corporate action

—

Competitive landscape — the read

vs mapped peers · 6M

1M 3M 6M 1Y 2Y All

Institutional money is backing ALKEM hardest (+₹1,013.7 Cr net). DRREDDY ranks #2 of 9 on flow (net buying +₹0 Cr). Filing momentum favours ZYDUSLIFE (+1). News & social buzz is most positive on DRREDDY.

#	Company	Inst. flow ₹Cr	Deals	Hi-impact	Filing mom.	Buzz	News
1	ALKEM	+₹1,013.7 Cr	13	—	—	-2	6
2	DRREDDYThis	—	—	—	—	+20	46
3	CIPLA	—	—	—	—	+19	44
4	SUNPHARMA	—	—	—	—	+15	45
5	TORNTPHARM	—	—	—	—	—	—
6	LUPIN	—	—	—	—	—	—
7	ZYDUSLIFE	—	—	1	+1	—	—
8	AUROPHARMA	—	—	—	—	—	—
9	MANKIND	—	—	—	—	—	—

Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.

Timeline — DRREDDY day by day

1M 3M 6M 1Y 2Y All

2026-06-16NewsDr. Reddy's Laboratories falls Tuesday, underperforms marketMarketWatch
2026-06-15NewsDr. Reddy's Laboratories (RDY) Faces 15% Drop Amid Market MovemeGuruFocus
2026-06-15NewsSun Pharmaceutical Industries Ltd Stock (INE044A01036): India pharma heavyweight in focus after receTopic · Generics
2026-06-15NewsDr. Reddy's Laboratories Ltd Stock (INE089A01023): U.S. Bosutinib Launch And Pre-market Drop Put ADRTopic · India
2026-06-15NewsApis India appoints Ankit Nagar as CFO and Pankaj Tripathi as GM-HRTopic · APIs
2026-06-15NewsDr. Reddy's Laboratories (RDY) Faces 15% Drop Amid Market MovemeGuruFocus
2026-06-15NewsDr. Reddy’s (NYSE: RDY) debuts first-to-market generic Bosulif 400mg in U.S.Stock Titan
2026-06-15NewsDr Reddy’s challenges Pfizer with US launch of BosutinibTopic · India
2026-06-15NewsDr. Reddy's Laboratories Ltd (RDY) Stock Analysis: Valuation Insights And Growth PotentialDirectorsTalk Interviews
2026-06-15NewsDr Reddy’s launches first-to-market generic Bosutinib in US oncology pushTopic · India
2026-06-15NewsDr. Reddy's launches first generic version of Bosulif in the US; stock in focusCNBC TV18
2026-06-13FilingDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 13, 2026, titlePress Release
2026-06-13NewsDr Reddy’s launches generic Bosulif in US, secures 180-day exclusivityTopic · India
2026-06-13NewsDr Reddy’s launches generic Bosulif in US, secures 180-day exclusivityTopic · India
2026-06-13NewsDr. Reddy's Labs oncology drug Bosutinib Tablets in United StatesTopic · India
2026-06-13NewsDr Reddy's launches Bosutinib 400mg in US, secures exclusivityscanx.trade
2026-06-13NewsDr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of BosulifBusiness Wire
2026-06-12FilingDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationCompliance
2026-06-12FilingKallam Satish Reddy has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SecuritieShareholding Disclosure
2026-06-12NewsIndia’s pharma role is expanding beyond genericsTopic · Generics
2026-06-11NewsDr. Reddy's Laboratories rallies Thursday, underperforms competitorsMarketWatch
2026-06-10FilingDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetInvestor Call
2026-06-10NewsDr. Reddy's Laboratories advances Wednesday, outperforms competitorsMarketWatch
2026-06-10NewsBuy, Sell Or Hold: IRCTC, SBI, Hindustan Copper, M&M, Paras Defence, Dr Reddy's Laboratories — Ask ProfitNDTV Profit

Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.

Filings that matter

2
Press ReleaseNeutral
a press release dated Jun 13, 2026, titled "Dr.
Source PDF →
1
ComplianceNeutral
Copy of Newspaper Publication
Source PDF →
2
Shareholding DisclosureNeutral
a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Source PDF →
2
Investor CallNeutral
Schedule of meet
Source PDF →